ALBO * Stock Overview
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Albireo Pharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$827.95 |
| 52 Week High | US$493.83 |
| 52 Week Low | US$382.76 |
| Beta | 1.04 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 48.59% |
Recent News & Updates
Recent updates
Shareholder Returns
| ALBO * | MX Biotechs | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how ALBO * performed against the MX Biotechs industry.
Return vs Market: Insufficient data to determine how ALBO * performed against the MX Market.
Price Volatility
| ALBO * volatility | |
|---|---|
| ALBO * Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: ALBO * has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ALBO *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 130 | Ron Cooper | www.albireopharma.com |
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases.
Albireo Pharma, Inc. Fundamentals Summary
| ALBO * fundamental statistics | |
|---|---|
| Market cap | Mex$16.70b |
| Earnings (TTM) | -Mex$2.38b |
| Revenue (TTM) | Mex$1.04b |
16.1x
P/S Ratio-7.0x
P/E RatioIs ALBO * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALBO * income statement (TTM) | |
|---|---|
| Revenue | US$57.39m |
| Cost of Revenue | US$2.55m |
| Gross Profit | US$54.84m |
| Other Expenses | US$185.99m |
| Earnings | -US$131.14m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.29 |
| Gross Margin | 95.56% |
| Net Profit Margin | -228.51% |
| Debt/Equity Ratio | 0% |
How did ALBO * perform over the long term?
See historical performance and comparison